Geulah Livshits

Geulah Livshits, PhD is a Senior Research Analyst at Chardan Capital Markets, specializing in biotechnology and pharmaceuticals.12 She is a highly regarded Wall Street analyst focusing on the healthcare sector, particularly advanced therapeutics in oncology and gene editing.

Professional Background

Geulah Livshits has established herself as a prominent figure in biotech equity research:

• She is ranked #301 out of 9,084 Wall Street Analysts and #806 out of 38,903 experts overall on TipRanks.1
• Her analysis covers 49 stocks in the healthcare sector, with a success rate of 40% and an average return of 22% per rating.1
• In 2021, she was recognized as the #1 female analyst on Wall Street.5
• More recently, she was ranked in the top 10 healthcare sector analysts of the past decade by TipRanks.3

Education and Expertise

• Geulah Livshits holds a PhD from Rockefeller University.2
• Her research focuses on advanced therapeutics, particularly in oncology and gene editing spaces.
• She has provided expert views on key questions facing the genetic medicines space, as published in BioPharma Dive.4

Professional Recognition

Geulah Livshits's expertise is widely recognized in the financial and biotechnology sectors:

• She has over 6,700 followers on TipRanks, indicating her influence in the field.1
• Her stock recommendations have shown a notable track record, with her best rating achieving an 800% return on Cabaletta Bio, Inc. (CABA) stock.1
• She frequently provides analysis and insights on various biotechnology companies, contributing to industry publications and discussions.

Geulah Livshits continues to be an influential voice in biotechnology investment analysis, providing valuable insights into the rapidly evolving healthcare and advanced therapeutics sectors.